IN-VITRO ACTIVITY OF GREPAFLOXACIN (OPC-17116) AGAINST ANAEROBIC-BACTERIA

In vitro activity of the quinolone grepafloxacin (OPC-17116) was compa red with that of ciprofloxacin, fleroxacin, clindamycin, imipenem, and metronidazole by using the NCCLS-approved Brucella-base-laked blood a gar dilution method and breakpoints, when available. Clindamycin, metr onidazole, and imipenem inhibited greater than or equal to 98% of Bact eroides fragilis at the breakpoint; grepafloxacin, ciprofloxacin, and fleroxacin inhibited 83%, 6%, and 0, respectively, at 2 mu g/ml. Grepa floxacin inhibited 39% of other B. fragilis group species isolates (80 ) at breakpoint (less than or equal to 2 mu g/ml) compared with 100% f or metronidazole and imipenem, 83% for clindamycin, 6% for ciprofloxac in, and 1% for fleroxacin. Grepafloxacin demonstrated substantially be tter activity against B. fragilis than did ciprofloxacin or fleroxacin ; overall activity against anaerobes was marginally better than that o f ciprofloxacin or fleroxacin.